Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate

Authors: Gonzalo Rodríguez-Berriguete, Benito Fraile, Fermín R de Bethencourt, Angela Prieto-Folgado, Nahikari Bartolome, Claudia Nuñez, Bruna Prati, Pilar Martínez-Onsurbe, Gabriel Olmedilla, Ricardo Paniagua, Mar Royuela

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

In this study was investigate IAPs in normal human prostate (NP), benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma (PC), and their involvement in apoptosis/proliferation via NF-kB (TNF-α, IL-1) stimulation.

Methods

Immunohistochemical and Western blot analyses were performed in 10 samples of normal prostates, 35 samples of BPH, 27 samples diagnosis of PIN (with low-grade PIN or high-grade PIN) and 95 samples of PC (with low, medium or high Gleason grades).

Results

In NP, cytoplasm of epithelial cells were positive to c-IAP1/2 (80% of samples), c-IAP-2 (60%), ILP (20%), XIAP (20%); negative to NAIP and survivin. In BPH, epithelial cells were immunostained to c-IAP1/2 (57.57%), c-IAP-2 (57.57%), ILP (66.6%), NAIP (60.6%), XIAP (27.27%), survivin (9.1%). Whereas low-grade PIN showed intermediate results between NP and BPH; results in high-grade PIN were similar to those found in PC. In PC, epithelial cells were immunostained to c-IAP1/2, c-IAP-2, ILP, NAIP, XIAP (no Gleason variation) and survivin (increasing with Gleason).

Conclusions

IAPs could be involved in prostate disorder (BPH, PIN and PC) development since might be provoke inhibition of apoptosis and subsequently cell proliferation. At the same time, different transduction pathway such as IL-1/NIK/NF-kB or TNF/NF-kB (NIK or p38) also promotes proliferation. Inhibitions of IAPs, IL-1α and TNFα might be a possible target for PC treatment since IAPs are the proteins that inhibited apoptosis (favour proliferation) and IL-1α and TNFα would affect all the transduction pathway involucrate in the activation of transcription factors related to survival or proliferation (NF-kB, Elk-1 or ATF-2).
Appendix
Available only for authorised users
Literature
1.
go back to reference Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ: Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol. 1999, 13: 376-384. 10.1210/me.13.3.376.CrossRefPubMed Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ: Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol. 1999, 13: 376-384. 10.1210/me.13.3.376.CrossRefPubMed
2.
go back to reference Deveraux QL, Reed JC: IAP family proteins--suppressors of apoptosis. Genes Dev. 1999, 13: 239-252. 10.1101/gad.13.3.239.CrossRefPubMed Deveraux QL, Reed JC: IAP family proteins--suppressors of apoptosis. Genes Dev. 1999, 13: 239-252. 10.1101/gad.13.3.239.CrossRefPubMed
3.
go back to reference Salvesen GS, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell. 1997, 91: 443-446. 10.1016/S0092-8674(00)80430-4.CrossRefPubMed Salvesen GS, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell. 1997, 91: 443-446. 10.1016/S0092-8674(00)80430-4.CrossRefPubMed
4.
go back to reference Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004, 64: 7183-7190. 10.1158/0008-5472.CAN-04-1918.CrossRefPubMed Schimmer AD: Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 2004, 64: 7183-7190. 10.1158/0008-5472.CAN-04-1918.CrossRefPubMed
5.
go back to reference Nuñez C, Cansino JR, Bethencourt F, Pérez-Utrilla M, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M: TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology. 2008, 53: 166-176. 10.1111/j.1365-2559.2008.03092.x.CrossRefPubMed Nuñez C, Cansino JR, Bethencourt F, Pérez-Utrilla M, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M: TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology. 2008, 53: 166-176. 10.1111/j.1365-2559.2008.03092.x.CrossRefPubMed
6.
go back to reference Royuela M, Rodríguez-Berriguete G, Fraile B, Paniagua R: TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol. 2008, 23: 1279-1290.PubMed Royuela M, Rodríguez-Berriguete G, Fraile B, Paniagua R: TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol. 2008, 23: 1279-1290.PubMed
7.
go back to reference Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T, Hirokawa K, Koike M: Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol. 2004, 76: 253-259. 10.1016/j.yexmp.2004.01.001.CrossRefPubMed Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T, Hirokawa K, Koike M: Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol. 2004, 76: 253-259. 10.1016/j.yexmp.2004.01.001.CrossRefPubMed
8.
go back to reference Endo T, Abe S, Seidlar HB, Nagaoka S, Takemura T, Utsuyama M, Kitagawa M, Hirokawa K: Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother. 2004, 53: 770-776. 10.1007/s00262-004-0534-8.CrossRefPubMed Endo T, Abe S, Seidlar HB, Nagaoka S, Takemura T, Utsuyama M, Kitagawa M, Hirokawa K: Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother. 2004, 53: 770-776. 10.1007/s00262-004-0534-8.CrossRefPubMed
9.
go back to reference Espinosa M, Cantú D, Herrera N, Lopez CM, De la Garza JG, Maldonado V, Melendez-Zajgla J: Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer. 2006, 6: 45-10.1186/1471-2407-6-45.CrossRefPubMedPubMedCentral Espinosa M, Cantú D, Herrera N, Lopez CM, De la Garza JG, Maldonado V, Melendez-Zajgla J: Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer. 2006, 6: 45-10.1186/1471-2407-6-45.CrossRefPubMedPubMedCentral
10.
go back to reference Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003, 9: 4914-4925.PubMed Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res. 2003, 9: 4914-4925.PubMed
11.
go back to reference Lagacé M, Xuan JY, Young SS, McRoberts C, Maier J, Rajcan-Separovic E, Korneluk RG: Genomic organization of the X-linked inhibitor of apoptosis and identification of a novel testis-specific transcript. Genomics. 2001, 77: 181-188. 10.1006/geno.2001.6635.CrossRefPubMed Lagacé M, Xuan JY, Young SS, McRoberts C, Maier J, Rajcan-Separovic E, Korneluk RG: Genomic organization of the X-linked inhibitor of apoptosis and identification of a novel testis-specific transcript. Genomics. 2001, 77: 181-188. 10.1006/geno.2001.6635.CrossRefPubMed
12.
go back to reference Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA, Salvesen GS: The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem J. 2005, 385: 1-10. 10.1042/BJ20041107.CrossRefPubMed Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA, Salvesen GS: The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem J. 2005, 385: 1-10. 10.1042/BJ20041107.CrossRefPubMed
13.
go back to reference Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, Notarangelo LD, Vezzoni P, Fearnhead HO, Duckett CS: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol. 2001, 21: 4292-4301. 10.1128/MCB.21.13.4292-4301.2001.CrossRefPubMedPubMedCentral Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, Notarangelo LD, Vezzoni P, Fearnhead HO, Duckett CS: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol. 2001, 21: 4292-4301. 10.1128/MCB.21.13.4292-4301.2001.CrossRefPubMedPubMedCentral
14.
go back to reference Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnston A, Lefebvre C, Kang X: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell. 1995, 80: 167-178. 10.1016/0092-8674(95)90461-1.CrossRefPubMed Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnston A, Lefebvre C, Kang X: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell. 1995, 80: 167-178. 10.1016/0092-8674(95)90461-1.CrossRefPubMed
15.
go back to reference Yamamoto K, Sakai H, Hadano S, Gondo Y, Ikeda JE: Identification of two distinct transcripts for the neuronal apoptosis inhibitory protein gene. Biochem Biophys Res Commun. 1999, 264: 998-1006. 10.1006/bbrc.1999.1615.CrossRefPubMed Yamamoto K, Sakai H, Hadano S, Gondo Y, Ikeda JE: Identification of two distinct transcripts for the neuronal apoptosis inhibitory protein gene. Biochem Biophys Res Commun. 1999, 264: 998-1006. 10.1006/bbrc.1999.1615.CrossRefPubMed
16.
go back to reference Maier JK, Balabanian S, Coffill CR, Stewart A, Pelletier L, Franks DJ, Gendron NH, MacKenzie AE: Distribution of neuronal apoptosis inhibitory protein in human tissues. J Histochem Cytochem. 2007, 55: 911-923. 10.1369/jhc.6A7144.2007.CrossRefPubMed Maier JK, Balabanian S, Coffill CR, Stewart A, Pelletier L, Franks DJ, Gendron NH, MacKenzie AE: Distribution of neuronal apoptosis inhibitory protein in human tissues. J Histochem Cytochem. 2007, 55: 911-923. 10.1369/jhc.6A7144.2007.CrossRefPubMed
17.
go back to reference Choi J, Hwang YK, Choi YJ, Yoo KE, Kim JH, Nam SJ, Yang JH, Lee SJ, Yoo KH, Sung KW, Koo HH, Im YH: Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci. 2007, 22: S17-23. 10.3346/jkms.2007.22.S.S17.CrossRefPubMedPubMedCentral Choi J, Hwang YK, Choi YJ, Yoo KE, Kim JH, Nam SJ, Yang JH, Lee SJ, Yoo KH, Sung KW, Koo HH, Im YH: Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci. 2007, 22: S17-23. 10.3346/jkms.2007.22.S.S17.CrossRefPubMedPubMedCentral
18.
go back to reference Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999, 341: 452-453. 10.1056/NEJM199908053410614.CrossRefPubMed Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC: Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med. 1999, 341: 452-453. 10.1056/NEJM199908053410614.CrossRefPubMed
19.
go back to reference Saitoh Y, Yaginuma Y, Ishikawa M: Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol. 1999, 15: 137-141.PubMed Saitoh Y, Yaginuma Y, Ishikawa M: Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol. 1999, 15: 137-141.PubMed
20.
go back to reference Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S: Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol. 2001, 19: 537-542.PubMed Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S: Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol. 2001, 19: 537-542.PubMed
21.
go back to reference Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000, 31: 1080-1085. 10.1053/he.2000.6496.CrossRefPubMed Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000, 31: 1080-1085. 10.1053/he.2000.6496.CrossRefPubMed
22.
go back to reference Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004, 100: 751-757. 10.1002/cncr.20039.CrossRefPubMed Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R: Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004, 100: 751-757. 10.1002/cncr.20039.CrossRefPubMed
23.
go back to reference Amantana A, London CA, Iversen PL, Devi GR: X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004, 3: 699-707.PubMed Amantana A, London CA, Iversen PL, Devi GR: X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther. 2004, 3: 699-707.PubMed
24.
go back to reference LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998, 17: 3247-3259. 10.1038/sj.onc.1202569.CrossRefPubMed LaCasse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998, 17: 3247-3259. 10.1038/sj.onc.1202569.CrossRefPubMed
25.
go back to reference Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H: Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol. 2004, 171: 1855-1860. 10.1097/01.ju.0000120317.88372.03.CrossRefPubMed Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H: Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol. 2004, 171: 1855-1860. 10.1097/01.ju.0000120317.88372.03.CrossRefPubMed
26.
go back to reference Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006, 5: 1087-1098. 10.1158/1535-7163.MCT-05-0375.CrossRefPubMed Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006, 5: 1087-1098. 10.1158/1535-7163.MCT-05-0375.CrossRefPubMed
27.
go back to reference Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001, 34: 207-212. 10.1007/s007950100017.CrossRefPubMed Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001, 34: 207-212. 10.1007/s007950100017.CrossRefPubMed
28.
go back to reference Vischioni B, Valk van der P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G: Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol. 2006, 37: 78-86. 10.1016/j.humpath.2005.09.022.CrossRefPubMed Vischioni B, Valk van der P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G: Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol. 2006, 37: 78-86. 10.1016/j.humpath.2005.09.022.CrossRefPubMed
29.
go back to reference Suh J, Rabson AB: NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J Cell Biochem. 2004, 91: 100-117. 10.1002/jcb.10729.CrossRefPubMed Suh J, Rabson AB: NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J Cell Biochem. 2004, 91: 100-117. 10.1002/jcb.10729.CrossRefPubMed
30.
go back to reference Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R: IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors. 2000, 18: 135-146. 10.3109/08977190009003239.CrossRefPubMed Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R: IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors. 2000, 18: 135-146. 10.3109/08977190009003239.CrossRefPubMed
31.
go back to reference Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M: The p38 transduction pathway in prostatic neoplasia. J Pathol. 2006, 208: 401-407. 10.1002/path.1910.CrossRefPubMed Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M: The p38 transduction pathway in prostatic neoplasia. J Pathol. 2006, 208: 401-407. 10.1002/path.1910.CrossRefPubMed
32.
go back to reference Verhagen AM, Coulson EJ, Vaux DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2001, 2: REVIEWS3009-10.1186/gb-2001-2-7-reviews3009.CrossRefPubMedPubMedCentral Verhagen AM, Coulson EJ, Vaux DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2001, 2: REVIEWS3009-10.1186/gb-2001-2-7-reviews3009.CrossRefPubMedPubMedCentral
33.
go back to reference Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y: Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol. 2005, 174: 2046-2050. 10.1097/01.ju.0000176459.79180.d1.CrossRefPubMed Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y: Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol. 2005, 174: 2046-2050. 10.1097/01.ju.0000176459.79180.d1.CrossRefPubMed
34.
go back to reference Royuela M, Arenas MI, Bethencourt FR, Sánchez-Chapado M, Fraile B, Paniagua R: Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol. 2002, 33: 299-306. 10.1053/hupa.2002.32227.CrossRefPubMed Royuela M, Arenas MI, Bethencourt FR, Sánchez-Chapado M, Fraile B, Paniagua R: Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol. 2002, 33: 299-306. 10.1053/hupa.2002.32227.CrossRefPubMed
35.
go back to reference de Miguel MP, Royuela M, Bethencourt FR, Santamaría L, Fraile B, Paniagua R: Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine. 2000, 12: 535-538. 10.1006/cyto.1999.0585.CrossRefPubMed de Miguel MP, Royuela M, Bethencourt FR, Santamaría L, Fraile B, Paniagua R: Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine. 2000, 12: 535-538. 10.1006/cyto.1999.0585.CrossRefPubMed
36.
go back to reference McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM: Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 2002, 51: 133-140. 10.1002/pros.10061.CrossRefPubMed McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM: Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate. 2002, 51: 133-140. 10.1002/pros.10061.CrossRefPubMed
37.
go back to reference Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM: Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003, 63: 4662-4670.PubMed Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM: Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003, 63: 4662-4670.PubMed
38.
go back to reference Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP, Ross JS: Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med. 2004, 128: 39-43.PubMed Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP, Ross JS: Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med. 2004, 128: 39-43.PubMed
39.
go back to reference Zhang M, Latham DE, Delaney MA, Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005, 24: 2474-2482. 10.1038/sj.onc.1208490.CrossRefPubMed Zhang M, Latham DE, Delaney MA, Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005, 24: 2474-2482. 10.1038/sj.onc.1208490.CrossRefPubMed
40.
go back to reference Chen CD, Sawyers CL: NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 2002, 22: 2862-2870. 10.1128/MCB.22.8.2862-2870.2002.CrossRefPubMedPubMedCentral Chen CD, Sawyers CL: NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 2002, 22: 2862-2870. 10.1128/MCB.22.8.2862-2870.2002.CrossRefPubMedPubMedCentral
41.
go back to reference Zou T, Rao JN, Guo X, Liu L, Zhang HM, Strauch ED, Bass BL, Wang JY: NF-kappaB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion. Am J Physiol Cell Physiol. 2004, 286: C1009-18. 10.1152/ajpcell.00480.2003.CrossRefPubMed Zou T, Rao JN, Guo X, Liu L, Zhang HM, Strauch ED, Bass BL, Wang JY: NF-kappaB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion. Am J Physiol Cell Physiol. 2004, 286: C1009-18. 10.1152/ajpcell.00480.2003.CrossRefPubMed
42.
go back to reference Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, Lee TH: cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res. 2009, 69: 1782-91. 10.1158/0008-5472.CAN-08-2256.CrossRefPubMed Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, Lee TH: cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res. 2009, 69: 1782-91. 10.1158/0008-5472.CAN-08-2256.CrossRefPubMed
Metadata
Title
Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate
Authors
Gonzalo Rodríguez-Berriguete
Benito Fraile
Fermín R de Bethencourt
Angela Prieto-Folgado
Nahikari Bartolome
Claudia Nuñez
Bruna Prati
Pilar Martínez-Onsurbe
Gabriel Olmedilla
Ricardo Paniagua
Mar Royuela
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-18

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine